Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model.

Slides:



Advertisements
Similar presentations
MODELING THE PROGRESSION AND TREATMENT OF HIV Presented by Dwain John, CS Department, Midwestern State University Steven M. Shechter Andrew J. Schaefer.
Advertisements

Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
Date of download: 5/28/2016 From: Association Between Exposure to Low to Moderate Arsenic Levels and Incident Cardiovascular Disease: A Prospective Cohort.
Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3): doi: /
Date of download: 5/28/2016 From: Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S.
Date of download: 5/28/2016 From: Effect of the Medicare Part D Coverage Gap on Medication Use Among Patients With Hypertension and Hyperlipidemia Ann.
Date of download: 5/28/2016 From: High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver.
Date of download: 5/29/2016 From: Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes Ann Intern Med.
Date of download: 5/29/2016 From: A Cost Analysis of Alternative Treatments for Duodenal Ulcer Ann Intern Med. 1995;123(9): doi: /
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Date of download: 5/31/2016 From: Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med. 2008;148(12): doi: /
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
Date of download: 5/31/2016 From: Polymorphonuclear Leukocytes in Non-Insulin-dependent Diabetes Mellitus: Abnormalities in Metabolism and Function Ann.
Date of download: 5/31/2016 From: Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts Ann Intern.
Date of download: 6/1/2016 From: Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia Ann Intern Med. 2000;133(11): doi: /
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/1/2016 From: Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms.
Date of download: 6/1/2016 From: Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules Ann Intern Med. 2003;138(9):
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):
Date of download: 6/3/2016 From: Chest Pain Relief by Nitroglycerin Does Not Predict Active Coronary Artery Disease Ann Intern Med. 2003;139(12):
Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
Date of download: 6/3/2016 From: Cost-Effectiveness of Treatment of Diabetic Macular Edema Ann Intern Med. 2014;160(1): doi: /M Markov.
Date of download: 6/9/2016 From: Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes Ann Intern Med.
Date of download: 6/21/2016 From: The Epidemiology of Prescriptions Abandoned at the Pharmacy Ann Intern Med. 2010;153(10): doi: /
Date of download: 6/21/2016 From: HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study Ann Intern Med. 2013;158(9):
Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.
Date of download: 6/22/2016 From: The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature Ann Intern Med. 1995;123(7):
Date of download: 6/22/2016 From: Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced.
Date of download: 6/22/2016 From: Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease:
Date of download: 6/23/2016 From: Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture Ann Intern Med. 2008;148(9):
Date of download: 6/23/2016 From: The Anticipated Clinical and Economic Effects of 90–90–90 in South Africa Ann Intern Med. Published online May 31, 2016.
Date of download: 6/23/2016 From: Meta-Analysis: Acupuncture for Low Back Pain Ann Intern Med. 2005;142(8): doi: /
Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.
Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Date of download: 6/25/2016 From: Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors.
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Date of download: 6/26/2016 From: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in.
Date of download: 6/26/2016 From: Variations in Mortality and Length of Stay in Intensive Care Units Ann Intern Med. 1993;118(10): doi: /
Date of download: 6/27/2016 From: Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost- Effectiveness Analysis.
Date of download: 6/29/2016 From: Predicting Future Functional Status for Seriously Ill Hospitalized Adults: The SUPPORT Prognostic Model Ann Intern Med.
Date of download: 7/1/2016 From: A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia Ann Intern Med. 2007;146(4): doi: /
Date of download: 7/6/2016 From: Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies: Model Estimates.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
Date of download: 7/6/2016 From: Can Inexpensive Signs Encourage the Use of Stairs? Results from a Community Intervention Ann Intern Med. 1998;129(5):
Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.
Date of download: 7/9/2016 From: Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac.
Date of download: 7/10/2016 From: Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial.
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
Date of download: 9/16/2016 From: Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Date of download: 9/17/2016 From: Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost- Effectiveness Analysis Ann.
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Date of download: 9/18/2016 From: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal Ann Intern Med. 2013;158(1):1-9.
Date of download: 9/19/2016 From: Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use: A Nationwide.
Ann Intern Med. 2010;153(7): doi: / Figure Legend:
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
From: Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States Ann Intern Med. 2016;165(1): doi: /M
Ann Intern Med. 1995;123(2): doi: / Figure Legend:
From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /
From: Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States Ann Intern Med. 2013;158(2):84-92.
Ann Intern Med. 2009;150(11): doi: / Figure Legend:
From: Treatment of Refractory Whipple Disease with Interferon-γ
From: Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy
From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 YearsA Comparative Modeling Study of Risk Ann Intern.
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
From: Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment ProgramA Randomized Trial Ann Intern Med.
Volume 373, Issue 9672, Pages (April 2009)
Presentation transcript:

Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med. 2008;148(3): doi: / Selected constructs in computer simulation.Constructs fall into 2 broad categories: genetic characteristics of the HIV strain and clinical characteristics of the patient. Genetic characteristics reflect the acquisition of mutations and affect clinical characteristics by altering the effectiveness of combination antiretroviral therapy (CART). Clinical characteristics affect the probability of dying of HIV-related or non–HIV-related causes. With time, combination antiretroviral therapy may give rise to HIV mutations through selection pressures on viral replication. As resistance accrues, the viral replication rate increases, and this in turn increases the probability that subsequent mutations will develop. Adherence, viral resistance, and other patient characteristics together determine the level of effectiveness of combination therapies, as manifested by changes in CD4 count and viral load. The simulation does not merely extrapolate long-term mortality risks based on short-term mortality data but rather predicts long-term mortality risks on the basis of the duration of the effectiveness of CART and other factors, including toxicity. Although determinants of the effectiveness of combination antiretroviral therapy may be unobserved or rarely observed, they may have a profound effect on survival and quality of life. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med. 2008;148(3): doi: / Cumulative incidence of resistance mutations (top) and combination antiretroviral therapy (CART) regimens (bottom) after 5 years, by treatment initiation threshold and viral load.Earlier therapy leads to more resistance mutations and to more regimens being used. Resistance mutations are defined as any mutation that may give rise to antiretroviral resistance in any drug class. A change in regimen is defined as a change in 2 or more antiretroviral drugs. We show results for age 40 years; results for other age groups did not differ greatly. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med. 2008;148(3): doi: / Quantity of therapy-related toxicity required to favor earlier rather than later initiation of combination antiretroviral therapy (CART).In each bar, as the hazard ratio of therapy-related toxicities increases, the different fills indicate the preferred treatment strategy, stratified by age and viral load. Therapy-related toxicity is manifested by greater non–HIV-related mortality. The upper bound used in our base-case analyses (3.8 × non–HIV- related mortality) favors starting therapy at a CD4 count of 500 cells/mm 3 at age 30 years and at age 40 years if the viral load is greater than copies/mL. If toxicity were below 2.4 × non–HIV-related mortality, starting therapy at a CD4 count of 500 cells/mm 3 would be preferred for all ages and viral loads examined. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/27/2016 From: Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med. 2008;148(3): doi: / Sensitivity analysis of how preferred treatment strategies vary with different parameter assumptions.The 3 graphs correspond to distinct assumptions about toxicity related to combination antiretroviral treatment (CART): high toxicity, as in our upper-bound base-case analysis (top); moderate toxicity (middle); and low toxicity (bottom). Within each graph, other model parameters are varied across plausible ranges. We analyzed only scenarios in which base-case results favored earlier treatment (age 30 years, all viral loads; age 40 years, viral loads of and copies/mL) because results favoring later treatment were unlikely to be robust. These analyses suggest that findings in favor of earlier treatment were generally stable, varying little with parameter assumptions. Numbers in parentheses are reference citations. *Reference refers to base-case estimate. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.